Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Iyer A
Authors: Iyer A, Vriens J, Dogan-Oruç F, van Koetsveld P, Hofland L,
Keywords: β-arrestin 1, CRISPR-Cas9, BON-1, knock-out, SSTR, SSA, Pan-NET,
#2983 Differential TGF-β Signalling in Typical and Atypical Bronchial Carcinoids
Introduction: Typical and atypical bronchial carcinoids (TBC and ABC) are well-differentiated neuroendocrine neoplasms (NEN). Metastatic BC having low to moderate mitotic count may still be treated with somatostatin analogues and mTOR inhibitors; however, TBC and ABC have been reported to respond very differently to therapy and an effective treatment algorithm is still lacking. TGF-β is known for its ability to activate mTOR pathway and induce epithelial mesenchymal transition, affecting cell pathophysiological capabilities such as proliferation, migration and tissue invasiveness.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Borges de Souza P
Authors: Borges de Souza P, Tagliatti V, Capobianco S, Ambrosio M, Chinnici S,
Keywords: Neuroendocrine neoplasms, bronchial carcinoids, TGF-β,
Introduction: Surufatinib is a targeted inhibitor of tyrosine kinases VEGFR1, 2, & 3, FGFR1, and CSF-1R. The safety profile was favorable in 2 completed studies (NCT02133157, NCT02267967) conducted in China. A recent phase 3 placebo controlled study (NCT02588170) confirmed safety, and demonstrated superior efficacy (PFS: 9.2 v 3.8 months) of Surufatinib in Chinese pts with advanced extra-pancreatic NETs (epNET).
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Dasari A, Paulson S, Sung M, Tucci C, Kauh J,
Keywords: Neuroendocrine Tumors, Pancreatic, Surufatinib,
#2827 Characterization of Epigenetic Modulation in Pancreatic Neuroendocrine Neoplasms
Introduction: Pancreatic neuroendocrine tumors (PanNETs) represent a rare and heterogeneous tumor entity. Despite advances in therapy cancer progression and resistance mechanisms are still challenging. Recent genome wide sequencing analyses in PanNETs identified a large number of mutated genes involved in epigenetic modulation.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Schmitz R
Authors: Schmitz R, Weißbach J, Kleinlein J, Schrader J, Grabowski P,
Keywords: PanNET, HDAC-Inhibition, SOCS3, lncRNA, Macrophages,
Introduction: Patients with SINET often have diffuse symptoms delaying diagnosis. In a patient survey it was observed that 1/3 of NET patients had a time span to diagnosis of > 5 years, with a median of 52 months. Here we assess the patients’ experience during that time period.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Holgersson K
Authors: Holgersson K, Ståhl E, Nilsson M, Grauers B, Mårtensson-Djäken E,
Keywords: SINET, patients' experience, interview,